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The “clogged pipe” analogy of coronary artery disease
(CAD) is questioned as a conceptual model to interpret
symptoms, evaluate prognosis, and guide therapy in ischemic
patients (1,2). Clinical studies indicate that most cardiac
events occur in patients who have angiographically mild
lesions (3). Histomorphologic evidence from the hearts of
patients who died suddenly supports the idea that vulnerable
plaques are thin-cap ﬁbroatheromas with a large necrotic
core and macrophage inﬁltration, which are more likely to
show lower luminal stenosis (4). This milieu favors pathwaysSee page 329that induce lipid peroxidation, necrotic core extension, and
rupture; procoagulant factors and platelet aggregation may
elicit thrombosis superimposed on the ruptured plaque (5).
This shift of the paradigm explaining coronary events as
driven by activated plaques is a stimulus to reconsider the
current approach to risk stratiﬁcation and choice of revascu-
larization treatment, which are both fundamentally based on
the angiographic evaluation of culprit obstructive atheroscle-
rosis (1,2). The unsolved enigma of the destiny of patients
with CAD should then be approached by deﬁning novel
algorithms, integrating clinical history, angiographic ﬁndings,
and noninvasive assessment of vulnerable plaques that may
produce recurrent events. Although the imaging tools to
identify them in vivo did not exist until recently, several studies
advocate the use, both for prognostication and as a guide to
therapy, of biomarkers reﬂecting their pathobiology (6).
According to these premises, the study by Eapen et al. (7),
in this issue of the Journal, has the self-declared scope to
determine an aggregate, pathway-speciﬁc risk score for*Editorials published in the Journal of the American College of Cardiology reﬂect the
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disclose.enhanced prediction of plaque rupture and related events in
CAD patients. It describes the utility (alone and in
combination) of 3 biomarkers, reﬂecting inﬂammation
(high-sensitivity C-reactive protein [CRP]), coagulation
(ﬁbrin degradation products [FDP]), and cell stress (heat
shock protein 70 [HSP70]) in the prediction of outcome in
a large (n ¼ 3,415) population of cardiovascular and heart
failure patients who underwent cardiac catheterization (8).
The prognostic value of the biomarker triad for overall and
cardiac mortality, acute myocardial infarction, and coronary
revascularization, was demonstrated beyond several estab-
lished risk factors, including an angiographic score of CAD
extension, indication to angiography, revascularization, renal
function, and left ventricular ejection fraction.
An adequate evaluation of a novel risk marker and/or
multimarker strategy requires measures of both discrimina-
tion and accuracy, and a sound research design (9). The 3
markers tested here have quite different analytical character-
istics and diagnostic accuracies. Assay ofCRP is standardized,
accurate, reproducible, and widely available, whereas FDP
and HSP70 assays have a less robust analytical background.
The weight of pathophysiological and clinical evidence, too,
is different among the 3 biomarkers. CRP elevation in coro-
nary patients has been associated with noncalciﬁed coronary
plaques with computed coronary tomography (10), and CRP
has shown promising association with cardiovascular risk.
However, many studies have shown minimal improvements
in the performance of risk algorithms that incorporate CRP
with other biomarkers (11). FDP elevation reﬂects either
activation of the coagulative cascade or inﬂammation, repre-
senting end products of plasmin on deposited ﬁbrin and
ﬁbrinogen degradation action. Both D-dimer and ﬁbrin
monomer increase in acute coronary syndromes, the latter
only showing a predictive value for mortality. D-dimer failed
to predict cardiovascular events in healthy populations or in
patients with stable CAD (12). HSPs are intracellular
proteins that increase in response to stress; HSP70, in
particular, protects cells from injury by reducing oxidation,
inﬂammation, and apoptosis, and by refolding damaged
proteins. Elevation of HSP70 occurs in several neoplastic and
systemic diseases, although its signiﬁcance is controversial
with regard to the natural history of atherosclerosis. The
distribution of HSP70 in human atherosclerotic plaques was
immunohistochemically demonstrated in relation to necrosis,
lipid, and macrophage accumulation, possibly reﬂecting their
response to stress (13). Conversely, increased HSP70 was
associated with a low risk for CAD in 421 patients evaluated
by angiography (14). On the whole, the evidence of a plausible
pathophysiological role in eliciting events from the vulnerable
plaque, although more consistent for CRP, seems scarce and
conﬂicting for both FDP and HSP70.
An adequate evaluation of novel risk markers requires a
representative at-risk population and an adequate number of
outcome events (9). According to enrollment criteria (8),
patients studied derive from a large “real-life,” “all-comers”
population, and present with a high prevalence of traditional
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and renal functions. Patients are heterogeneous with respect
to the presence and extent of CAD on angiography and to
clinical presentation (8). This feature may limit the repro-
ducibility of results, and indicate the need for their validation
in large, homogeneous populations.
Appraisal of novel markers should also report the degree
to which they add to the prognostic information provided by
standard risk markers (9). Although the predictive value of
CRP, FDP, and HSP70 was adjusted for multiple con-
founders, troponins and B-type natriuretic peptides, which
have shown prognostic value in similar populations, were not
considered, as well as relevant clinical information (under-
lying etiology beyond CAD, left ventricular diastolic and
right ventricular function, evidence of inducible ischemia,
success and completeness of revascularization) and use of
drugs and/or devices other than statins and antiplatelet
agents, known to inﬂuence prognosis.
The investigators’ interpretation of the prognostic value of
CRP, FDP, and HSP70 in their population, characterized
by a high prevalence of risk factors and coronary athero-
sclerosis, is that this multimarker strategy may identify
subsets at risk for events favored by plaque instability, driven
by pathways such as inﬂammation, cellular stress, and
coagulation. Actually, these pathways may be not considered
as speciﬁc of coronary involvement, and biomarker elevation
could reﬂect ongoing systemic or neoplastic diseases, as
pointed out by their predictive value for noncardiac mortality
(47% of deaths in this series).
Finally, the real clinical value of every novel single and/or
multimarker approach should be assessed by its effect on
patient management and outcomes (9). Although inﬂam-
mation is currently targeted by aspirin and statin use, and
low-dose colchicine (which inhibits neutrophil function)
appears effective for the prevention of cardiovascular events
in stable CAD patients (15), anticoagulant drugs are not
currently indicated for prevention of CAD-related events.
The possible pharmacological modulation of HSP70 expres-
sion is still under investigation.
All in all, we should consider this retrospective study as
a proof-of-principle, hypothesis-generating investigation.
If its remarkable ﬁndings will ﬁnd future conﬁrmation in
large, well-designed investigations in homogeneous pop-
ulations, there will be the possibility to test whether thera-
pies targeting these 3 speciﬁc pathways could be effectiveon a biomarker level and predictive of occurrence of coro-
nary events.
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